Back to search results
NCT05161078

Improving Continuous Renal Replacement Therapy Outcomes in Neonates and Infants Through Interdisciplinary Collaboration

Enrolling by Invitation
Not specifiedAll AgesObservational
Children's Hospital Medical Center, Cincinnati
~1,000 participants
Updated 2026-03-23 on ClinicalTrials.gov
What's tested:CARPEDIEM

At a glance

Recruiting sites
0 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of CARPEDIEM filters to meet prescribed treatment length
Measured over 24 hours
+2 more outcomes measured

Conditions

Acute Kidney Injury
Chronic Kidney Diseases
Renal Dialysis

Explore related trials

Acute Renal FailureChronic Kidney DiseaseHemodialysis

Where it's being run

9 sites across 9 states
California1
Colorado1
Georgia1
Michigan1
Nebraska1
Ohio1
Texas1
Washington1

Study leadership

  • Cara Slagle, MD · PRINCIPAL_INVESTIGATOR · Cincinnati Children's

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Treated with CARPEDIEM as part of standard of care at a participating institution within the United States

Exclusion

Parents/legally authorized representative unable or unwilling to provide consent

What this trial measures

  • Number of CARPEDIEM filters to meet prescribed treatment length24 hours

    Comparing actual time of treatment of each CARPEDIEM filter to the initial prescribed length of treatment at the time of filter initiation

  • Rate of patient survivalthrough hospital discharge, an average of less than 1 year

    Percent of patients treated with the CARPEDIEM who survive to hospital discharge

  • Rate of renal recoverythrough hospital discharge, an average of less than 1 year

    Excluding patients with End Stage Renal Disease (ESRD), percent of patients treated with the CARPEDIEM who recover baseline renal function as measured by liberation from dialysis and serum creatinine returning to within less than a 50% increase over baseline.